Warfarin Sodium Tablets — Class II drug recall D-0348-2023
Terminated recall by RISING PHARMACEUTICALS, reported 2023-03-01, distributed nationwide. Failed Impurities/Degradation Specifications
| Recall number | D-0348-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | RISING PHARMACEUTICALS, East Brunswick, NJ, United States |
| Recall initiated | 2023-02-15 |
| Classified | 2023-02-23 |
| Reported by FDA | 2023-03-01 |
| Terminated | 2024-06-14 |
| Distributed | Nationwide (US) |
| Quantity | 12,216 bottles |
| Reason classes | specification failure |
| NDC | 57237-0119-01 |
| Lot numbers | NB101596 |
| Expiration dates | 2023-04-30 |
Product
Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC# 57237-119-01
Reason for recall
Failed Impurities/Degradation Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0348-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.